On the third day of ADA 2024, four cardiometabolic-related news items have been observed from Senseonics, Altimmune, Fractyl Health, and Gan & Lee. Below, FENIX provides context and analysis for the announcements.
On the second day of ADA 2024, six cardiometabolic-related news items have been observed from Insulet, Medtronic, Terns Pharmaceuticals, MannKind, Tandem, and Altimmune. Below, FENIX provides context and analysis for the announcements.
Three cardiometabolic-related news items have been observed: Merck initiated a new Ph2a trial of efinopegdutide in MASH (view CT.gov record); Lexicon Pharmaceuticals published a cost-effective analysis of Inpefa in diabetes and HF (view press release); Novo Nordisk (view press release), Tandem Diabetes Care (view press release), and Altimmune (view press release) announced data presentations at ADA 2024. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from UK’s NICE, Lilly, Altimmune, and Dexcom. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk/Metaphore Biotechnologies, Altimmune, Xeris, MannKind, and Viatris. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Altimmune, Lilly, 89bio, Ypsomed, and JDRF. Below, FENIX provides highlights and insights into the respective news items.
Two cardiometabolic-related news items have been observed: Pfizer announced topline results from the danuglipron (BID oral GLP-1RA) Ph2b clinical trial and disclosed it will not be advancing the formulation into Ph3 (view press release); and Altimmune announced positive topline results from the Ph2 MOMENTUM study evaluating pemvidutide for the treatment of obesity (view press release). Following the results, Altimmune’s stock increased ~18%. Below, FENIX provides highlights and insights for the respective news items, including thoughts on how the Ph2b danuglipron data may impact Pfizer’s decision not to advance BID danuglipron.
A series of cardiometabolic-related news items have been observed from OrsoBio, Diamyd, Esperion, Altimmune, MannKind, and Viatris. Below, FENIX provides highlights and insights into the respective news items.
Four cardiometabolic-related news items have been observed: FDA granted Fast Track Designation to Altimmune’s pemvidutide for the treatment of NASH (view press release); Diamyd announced results from a retrospective follow-up study of two prior trials, DiAPREV-IT and DiAPREV-IT2 (view press release); Viking (press release) and Merck (press release; slides) hosted their respective Q3 ’23 earnings call. Below, FENIX provides highlights and insights for the respective news items.
Four cardiometabolic-related news items have been observed: Entera Bio and OPKO Biologics entered into a research collaboration agreement for OPKO’s long-acting GLP-2 peptide and certain oxyntomodulin (OXM) analogs (view press release); Dexcom announced Dexcom ONE has been launched in France (with reimbursement) for patients two years of age and older with T1DM and T2DM, who are undergoing intensive insulin therapy (view press release); Altimmune announced the completion of dosing in its 48-week Ph2 MOMENTUM trial, evaluating the safety and efficacy of pemvidutide in patients with obesity or overweight (view press release); and Septerna announced it signed a definitive asset purchase agreement with Vertex for an undisclosed discovery-stage GPCR program (view press release). Below, FENIX provides highlights and insights into the respective news items.